Algert Global LLC Has $145,000 Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Algert Global LLC lowered its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 90.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 19,802 shares of the company's stock after selling 193,663 shares during the quarter. Algert Global LLC's holdings in Vir Biotechnology were worth $145,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new position in shares of Vir Biotechnology during the 4th quarter worth approximately $60,000. PNC Financial Services Group Inc. grew its position in shares of Vir Biotechnology by 31.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock valued at $61,000 after purchasing an additional 1,999 shares during the period. KBC Group NV grew its position in Vir Biotechnology by 136.5% during the fourth quarter. KBC Group NV now owns 8,970 shares of the company's stock valued at $66,000 after acquiring an additional 5,177 shares during the period. CIBC Asset Management Inc purchased a new stake in Vir Biotechnology during the fourth quarter valued at about $74,000. Finally, Syon Capital LLC purchased a new stake in Vir Biotechnology during the fourth quarter valued at about $77,000. Hedge funds and other institutional investors own 65.32% of the company's stock.

Insider Buying and Selling

In other news, EVP Verneuil Vanina De sold 7,373 shares of the business's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total value of $67,389.22. Following the completion of the transaction, the executive vice president now owns 79,460 shares of the company's stock, valued at $726,264.40. The trade was a 8.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Backer Marianne De sold 79,712 shares of the stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total value of $474,286.40. Following the transaction, the chief executive officer now owns 769,505 shares of the company's stock, valued at approximately $4,578,554.75. This trade represents a 9.39% decrease in their position. The disclosure for this sale can be found here. Insiders sold 98,049 shares of company stock worth $649,232 in the last quarter. Insiders own 15.60% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on VIR. The Goldman Sachs Group decreased their target price on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Barclays upped their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a report on Friday, February 28th. Finally, Needham & Company LLC decreased their price objective on Vir Biotechnology from $19.00 to $14.00 and set a "buy" rating for the company in a report on Monday, May 12th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $32.86.

Vir Biotechnology Price Performance

Shares of VIR stock traded up $0.04 during trading on Monday, reaching $4.64. The company had a trading volume of 1,402,301 shares, compared to its average volume of 1,373,519. The firm's 50 day simple moving average is $5.92 and its two-hundred day simple moving average is $7.81. The company has a market capitalization of $641.42 million, a PE ratio of -1.18 and a beta of 1.36. Vir Biotechnology, Inc. has a one year low of $4.32 and a one year high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.05). The firm had revenue of $3.03 million for the quarter, compared to analyst estimates of $8.59 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm's quarterly revenue was down 94.6% compared to the same quarter last year. During the same period last year, the business earned ($0.48) earnings per share. Analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).